1. Home
  2. TKC vs EWTX Comparison

TKC vs EWTX Comparison

Compare TKC & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Turkcell Iletisim Hizmetleri AS

TKC

Turkcell Iletisim Hizmetleri AS

N/A

Current Price

$4.82

Market Cap

4.4B

ML Signal

N/A

Logo Edgewise Therapeutics Inc.

EWTX

Edgewise Therapeutics Inc.

N/A

Current Price

$46.41

Market Cap

4.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TKC
EWTX
Founded
1993
2017
Country
Turkey
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
4.3B
IPO Year
2001
2021

Fundamental Metrics

Financial Performance
Metric
TKC
EWTX
Price
$4.82
$46.41
Analyst Decision
Buy
Strong Buy
Analyst Count
2
13
Target Price
$7.38
★ $55.42
AVG Volume (30 Days)
★ 2.3M
1.6M
Earning Date
11-09-2026
11-04-2026
Dividend Yield
★ 3.83%
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ 8.86
Revenue
N/A
N/A
Revenue This Year
$30.23
N/A
Revenue Next Year
$27.60
N/A
P/E Ratio
$26.98
★ $5.19
Revenue Growth
N/A
N/A
52 Week Low
$4.46
$19.76
52 Week High
$7.18
$48.78

Technical Indicators

Market Signals
Indicator
TKC
EWTX
Relative Strength Index (RSI) 50.16 62.79
Support Level $4.49 $37.22
Resistance Level $5.22 $47.36
Average True Range (ATR) 0.09 3.14
MACD 0.04 0.94
Stochastic Oscillator 68.60 80.22

Price Performance

Historical Comparison
TKC
EWTX

About TKC Turkcell Iletisim Hizmetleri AS

Turkcell Iletisim Hizmetleri AS provides mobile telephone services in Turkey. The firm's services portfolio includes mobile and fixed voice, data, TV, and digital services over its network. The firm also operates in the Turkish Republic of Northern Cyprus, Belarus, the Netherlands, and Ukraine. It has three main reportable segments: Turkcell Turkiye, Techfin, and Other. The Turkcell Turkiye segment, which derives the majority of revenue, comprises mainly telecommunication and technology services activities.

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.

Share on Social Networks: